Shares of TransCode Therapeutics, Inc. (RNAZ) are surging over 60% on Thursday morning after the company announced pre-clinical data supporting therapeutic potential of TTX-MC138(MN-anti-miR10b) in metastatic breast cancer.
RNAZ is currently trading at $4.24, up $1.62 or 61.8321%, on the Nasdaq, on a volume of 89 million shares, far above average volume of 1.1 million shares. The stock has traded between $2.35 and $7.00 in the 52 week period.
TransCode Therapeutics announced that preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. Imaging study confirms the biodistribution of TTX-MC138 in models of metastatic cancer, supporting TransCode's TTX platform for delivery of RNA targeted therapy to metastatic solid tumors.
TransCode expects to file an exploratory investigational new drug (eIND) application for TTX-MC138 in the first quarter of 2022 to support a Phase 0 study in patients with metastatic cancer.
For comments and feedback: editorial@rttnews.com